Modulation of osteoclast differentiation

摘要

The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associated with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of AQP-9 inhibitor is phloretin which has been shown to inhibit osteoclast differentiation, following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for prevention and treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators.

主权项

1. A method of modulating unbalanced osteoclast differentiation, in the treatment of osteoporosis, periodontal disease, aseptic loosening of prosthetic implants, or a bone disease manifested by excess bone loss, the method comprising:
administering a therapeutically effective amount of phloretin to a subject in need thereof wherein the therapeutically effective amount inhibits aquaporin-9 (AQP-9) activity in one or more of osteoclast cells and osteoclast precursor cells.